Loading…
Gain Therapeutics, Inc. is projected to rise to $1.91 by 2027, a +6% move from its current price of $1.80. GANX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.74 | $1.80 | $1.86 | -0.04% |
| Jul 14 | $1.71 | $1.80 | $1.89 | -0.09% |
| Jul 15 | $1.69 | $1.80 | $1.91 | -0.13% |
| Jul 16 | $1.68 | $1.80 | $1.93 | -0.18% |
| Jul 17 | $1.66 | $1.80 | $1.94 | -0.22% |
| Jul 18 | $1.65 | $1.80 | $1.95 | -0.26% |
| Jul 19 | $1.64 | $1.79 | $1.97 | -0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.64 | $1.79 | $1.97 | -0.31% |
| Week 2 | $1.57 | $1.79 | $2.04 | -0.62% |
| Week 3 | $1.52 | $1.78 | $2.09 | -0.92% |
| Week 4 | $1.48 | $1.78 | $2.13 | -1.23% |
| Week 5 | $1.44 | $1.77 | $2.17 | -1.53% |
| Week 6 | $1.41 | $1.77 | $2.21 | -1.84% |
| Week 7 | $1.38 | $1.76 | $2.24 | -2.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gain Therapeutics, Inc. is a biotechnology company that develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics was founded in 2017 and is based in Bethesda, Maryland.
GANX is a biotechnology company with a focused pipeline of small molecule therapeutics. The asset trades at $1.81 and has a market cap of $77.2M, ranking 4300 by market capitalization.
Near-term forecasts show a flat price trajectory in 2026 with an average price of $1.81 and an estimated ROI of 0%. Longer-horizon projections indicate meaningful upside: 2030 average price $2.66 with ROI 46.8%, 2040 average price $5.16 with ROI 185%, and 2050 average price $11.37 with ROI 528.3%, all signaling a bullish long-term outlook.
A major floor 20.4% below — a decisive break under it would weaken the trend.
The nearest floor, 8.9% below — buyers have tended to step in here.
The nearest ceiling, 12.8% above — a clean break opens room to run.
A major ceiling 69.4% above — clearing it would confirm fresh momentum.
Key GANX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GANX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.81 | Sell | $1.82 | Sell |
| MA 10 | $1.87 | Sell | $1.83 | Sell |
| MA 20 | $1.82 | Sell | $1.83 | Sell |
| MA 50 | $1.81 | Sell | $1.85 | Sell |
| MA 100 | $1.98 | Sell | $1.95 | Sell |
| MA 200 | $2.21 | Sell | $2.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.29 | Neutral |
| Stoch RSI (14) | 16.58 | Buy |
| CCI (20) | -15.29 | Neutral |
| Williams %R (14) | -74.19 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 1.69 | Buy |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 25.81 | Neutral |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 25.13 | Buy |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 1.76 | Buy |
| ADX (14) | 9.13 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is Neutral with RSI14 at 50. The 30-day moving average is $1.81 (SMA50) and $2.20 (SMA200).
Near-term support is at $1.64 and resistance at $2.03. The 30-day price range spans from $1.40 to $2.34, reflecting subdued volatility over the near term (annualized volatility ~70%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.59 | $1.80 | $2.14 | 0% | Neutral | |
| $1.48 | $1.91 | $2.63 | +6% | Neutral | |
| $1.35 | $1.80 | $2.59 | 0% | Neutral | |
| $1.47 | $2.03 | $3.02 | +13% | Neutral | |
| $1.87 | $2.65 | $4.07 | +47% | Bullish | |
| $2.06 | $2.99 | $4.70 | +66% | Bullish | |
| $2.18 | $3.24 | $5.21 | +80% | Bullish | |
| $2.08 | $3.15 | $5.18 | +75% | Bullish | |
| $2.03 | $3.15 | $5.27 | +75% | Bullish | |
| $2.25 | $3.56 | $6.06 | +98% | Bullish | |
| $3.07 | $5.32 | $9.73 | +195% | Bullish | |
| $5.57 | $11.39 | $23.15 | +533% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.59 | $1.80 | $2.12 | +0.00% |
| August 2026 | $1.44 | $1.71 | $2.09 | -5.12% |
| September 2026 | $1.44 | $1.73 | $2.15 | +1.24% |
| October 2026 | $1.44 | $1.74 | $2.19 | +0.62% |
| November 2026 | $1.38 | $1.68 | $2.13 | -3.65% |
| December 2026 | $1.36 | $1.67 | $2.14 | -0.44% |
Click any year to see its month-by-month GANX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GANX price prediction for 2026 points to an average of $1.80 (low $1.59, high $2.14) — a potential gain of 0% on today's $1.80. A consolidation phase looks the most probable path here.
In 2027, GANX is projected to trade between $1.48 and $2.63, averaging $1.91 — a potential gain of +6% from today's $1.80. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Gain Therapeutics, Inc.'s 2028 outlook centres on $1.80, within a $1.35 to $2.59 range. That is -6% versus the projected 2027 average. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, GANX could reach as high as $3.02, with a base case around $2.03 and support toward $1.47 — roughly +13% from $1.80. Price action looks broadly range-bound.
Expect GANX to range from $1.87 to $4.07 through 2030. The $2.65 average target implies a +47% move from current prices. That is up +31% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The GANX price prediction for 2031 points to an average of $2.99 (low $2.06, high $4.70) — a potential gain of +66% on today's $1.80. Momentum favours further upside here.
In 2032, GANX is projected to trade between $2.18 and $5.21, averaging $3.24 — a potential gain of +80% from today's $1.80. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Gain Therapeutics, Inc.'s 2033 outlook centres on $3.15, within a $2.08 to $5.18 range. That is -3% versus the projected 2032 average. That marks a +75% change versus current levels. Momentum favours further upside here.
By 2034, GANX could reach as high as $5.27, with a base case around $3.15 and support toward $2.03 — roughly +75% from $1.80. Buyers look set to stay in control over this stretch.
Expect GANX to range from $2.25 to $6.06 through 2035. The $3.56 average target implies a +98% move from current prices. That is up +13% on the projected 2034 average. Momentum favours further upside here.
The GANX price prediction for 2040 points to an average of $5.32 (low $3.07, high $9.73) — a potential gain of +195% on today's $1.80. Buyers look set to stay in control over this stretch.
In 2050, GANX is projected to trade between $5.57 and $23.15, averaging $11.39 — a potential gain of +533% from today's $1.80. That is up +114% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GANX today (≈ 555.555556 GANX) could be worth
$6,328.96
+$5,328.96 (+533%) by 2050 · US Dollar
Based on the average projected GANX price of $11.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GANXwould be worth at today's price.
$1,000 invested in GANX on Jul 10, 2025 (≈ 564.971758 GANX) would be worth
$1,016.95
+$16.95 (+1.7%) today · 1.02× · US Dollar
Based on a GANX entry price of $1.77 vs. today's $1.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.91 | $942.41 | -5.8% |
| 1 month ago | $1.64 | $1,097.56 | +9.8% |
| 3 months ago | $1.8 | $1,000 | +0.0% |
| 6 months ago | $2.14 | $841.12 | -15.9% |
| 1 year ago | $1.77 | $1,016.95 | +1.7% |
| All time (5.0y) ago | $9.97 | $180.54 | -81.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GANX forecast.
Our base-case forecast reaches $3.60 around 2040.
Implied market cap at $3.60: $153.55M
2030 forecast: average price $2.66 with ROI 46.8% and bullish sentiment. 2040 forecast: average price $5.16 with ROI 185% and bullish sentiment. 2050 forecast: average price $11.37 with ROI 528.3% and bullish sentiment.
The multi-year outlook shows substantial upside potential beyond 2029, with higher average prices and double- to triple-digit ROI in the 2030–2050 window. These are estimates and not guarantees, and actual results may differ.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $2.66 with an estimated ROI of 46.8%, with sentiment Bullish.
Near-term forecasts are Neutral, with longer-term projections turning Bullish. The 2026 average price is $1.81 (ROI 0%), rising to a 2050 average of $11.37 (ROI 528.3%). These are estimates, not guarantees.
Yes. The 2040 forecast shows an average price of $5.16 with ROI 185% and a Bullish sentiment.
Current price is $1.81 and market cap is $77.2M.
RSI14 is 50 (Neutral). SMA50 is $1.81 and SMA200 is $2.20. Support is at $1.64 and resistance at $2.03. The 30-day range is $1.40–$2.34.
Gain Therapeutics, Inc. Community Discussion
0Share your Gain Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.